Ascletis is committed to developing and producing safe, effective, and affordable oral COVID-19 drugs globally. As a leading biotechnology company in China, Ascletis has submitted a new drug clinical trial application for the new coronavirus oral drug candidate RdRp inhibitor ASC

2024/06/0522:53:32 science 1152

On July 6, Ascletis Pharmaceuticals announced that after completing the pre-IND consultation, Ascletis has submitted COVID-19 (new crown) oral drug candidate polymerase (RdRp) inhibitor ASC10 to FDA New drug clinical trial (IND) application.

ASC10 is an oral small molecule drug candidate that is fully independently developed by Ascletis and has complete global development and commercialization rights. The application for clinical trials of new drugs in the United States will accelerate the ASC10 international multi-center clinical research and further enhance the layout of Ascletis’ COVID-19 oral drug pipeline.

ASC10 is a new oral small molecule drug candidate targeting the RdRp of the new coronavirus. ASC10 is an oral dual prodrug of the antiviral nucleoside analog ASC10-A, which has potent inhibitory effects on the novel coronavirus RdRp. In preclinical studies, ASC10-A demonstrated excellent in vitro antiviral activity against a variety of new coronavirus mutant strains, including and .

Ascletis is committed to the global development and production of safe, effective, and affordable oral COVID-19 drugs. As a leading biotechnology company in China, Ascletis has submitted a new drug clinical trial application for the new coronavirus oral drug candidate RdRp inhibitor ASC10 to the US FDA. At the same time, the ASC10 Chinese new drug clinical trial application work is proceeding as planned.

According to the Insight database, there are currently 23 RdRp inhibitors under research in the world for new crown , of which 5 have been approved for marketing, and 6 have entered the clinical stage.

Six RdRp inhibitors entering the clinical stage around the world in the field of COVID-19

Ascletis is committed to developing and producing safe, effective, and affordable oral COVID-19 drugs globally. As a leading biotechnology company in China, Ascletis has submitted a new drug clinical trial application for the new coronavirus oral drug candidate RdRp inhibitor ASC - DayDayNews

From: Insight database

This article comes from Insight database

science Category Latest News